Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Beyond Biomarkers: Exploring the Diverse Potential of a Novel Phosphoprotein in Lung Cancer Management Publisher Pubmed



Rostami A1 ; Ranjbar E2 ; Amiri S3 ; Ezzatifar F4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Source: Journal of Cellular and Molecular Medicine Published:2024


Abstract

In addressing the challenges of lung cancer, attention has increasingly turned to molecular diagnostics and targeted therapies, with nucleolin (NCL) assuming a pivotal role, especially in non-small cell lung cancer. The aberrant activity and cellular distribution of NCL act as crucial biomarkers for early detection and treatment monitoring, showing a strong correlation with disease progression and patient prognosis. Elevated NCL levels signal advanced disease and poorer outcomes, underscoring its significance in evaluating disease severity and therapeutic response. Strategies targeting the molecular interactions of NCL have spurred innovative approaches to inhibit tumour growth, overcome drug resistance and improve treatment efficacy. These advancements are paving the way for personalized therapies tailored to the unique molecular profiles of patients' tumours. Consequently, NCL stands at the forefront of lung cancer management, symbolizing the move towards more precise and individualized oncology care, and marking substantial progress in therapeutic development. © 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Related Docs
1. Aptamer-Functionalized Micelles for Targeted Cancer Therapy, Aptamers Engineered Nanocarriers for Cancer Therapy (2022)
2. Amino-Modified-Silica-Coated Gadolinium-Copper Nanoclusters, Conjugated to As1411 Aptamer and Radiolabeled With Technetium-99 M As a Novel Multimodal Imaging Agent, Bioorganic Chemistry (2022)
3. Recent Advancements in Aptamer-Bioconjugates: Sharpening Stones for Breast and Prostate Cancers Targeting, Journal of Drug Delivery Science and Technology (2019)
4. Aptamer Hybrid Nanocomplexes As Targeting Components for Antibiotic/Gene Delivery Systems and Diagnostics: A Review, International Journal of Nanomedicine (2020)
5. Inhibition of Mir-155 in Mcf-7 Breast Cancer Cell Line by Gold Nanoparticles Functionalized With Antagomir and As1411 Aptamer, Journal of Cellular Physiology (2020)
6. As1411 Aptamer-Anionic Linear Globular Dendrimer G2-Iohexol Selective Nano-Theranostics, Scientific Reports (2017)
Experts (# of related papers)
View all Related Experts
Mehdi Shafee Ardestani (2)
Massoud Amanlou (1)